Overview of Upcoming Virtual Investor Events
Kura Oncology, Inc. (NASDAQ: KURA), a biopharmaceutical firm dedicated to advancing precision medicine in cancer treatment, is gearing up for two virtual events highlighting their groundbreaking farnesyl transferase inhibitor (FTI) program. These events are poised to showcase Kura's leadership in targeting cancer signaling pathways, particularly in solid tumors and hematologic malignancies.
Event Details
The first event, focusing on the FTI Preclinical Program Review, is scheduled for Tuesday, September 16. It will commence at 1:30 p.m. PT / 4:30 p.m. ET. This session aims to discuss the scientific principles, mechanisms of action, and the preclinical results that support the combination of FTIs with various targeted therapies including tyrosine kinase inhibitors (TKIs) and RAS inhibitors. Attendees can expect insights on how these combinations may enhance treatment efficacy for solid tumors.
Key Insights on Synergistic Treatments
Participants will delve into the different ways FTIs can work in conjunction with other therapies, paving the way for innovative treatment protocols that offer hope to patients with difficult-to-treat cancers. The potential of these combinations to transform existing treatment strategies will be a central theme of the discussion.
Second Event: Insights from ESMO Congress
Following this, the second virtual event will take place on Saturday, October 18, starting at 10:30 a.m. PT / 1:30 p.m. ET. This event will center around clinical data presented at the notable 2025 European Society for Medical Oncology (ESMO) Congress, focusing particularly on KO-2806, Kura's next-generation FTI. Attendees will gain exclusive insights into new clinical data and findings that have been generated through rigorous trials.
Focus on KO-2806 and Resistance Mechanisms
KO-2806 is noteworthy as it aims to address the complexities of drug resistance in cancer treatments. Insights regarding its effectiveness and potential to overcome therapeutic resistance mechanisms will be a highlight, making this session particularly relevant for oncology professionals and investors alike.
Accessing the Webcasts
For those interested in attending, live audio webcasts will be available in the Investors section of Kura's website. After the events, recorded replays will also be accessible for on-demand viewing, ensuring that stakeholders can catch up on vital information and updates at their convenience.
Additional Conference Details
At the ESMO Congress, Kura plans to present several key studies regarding their innovative treatments:
- Farnesyltransferase inhibitor KO-2806 combined with cabozantinib in renal cell carcinoma: Preliminary results from FIT-001 phase 1 trial.
Scheduled for October 18, 2025, at 12:00 PM CEST, this presentation (Publication Number 2604P) will explore the early results from an exciting clinical trial. - A phase 1 study of KO-2806 as a monotherapy in advanced solid tumors.
Scheduled for October 19, 2025, at 12:00 PM CEST, it will outline the advancements in treatment approaches with publication number 981P. - Tipifarnib and alpelisib in head and neck squamous cell carcinoma: Phase 1 results from KURRENT-HN.
This presentation is scheduled for October 20, 2025, at 12:00 PM CEST (Publication Number 1349P).
The three posters presented at the congress will be available for viewing in the "Pipeline/Posters and Presentations" section on Kura's website following their presentations, providing further details for those who cannot attend the live sessions.
More About Kura Oncology
Kura Oncology is dedicated to making advancements in the field of oncology through innovative drug development. Their pipeline features a variety of small molecule drug candidates aimed at targeting critical cancer signaling pathways. Among their promising candidates is ziftomenib, a menin inhibitor focused on specific genetic drivers of acute myeloid leukemia. Kura is pioneering the use of menin inhibition and farnesyl transferase inhibition to tackle challenges in treating complex solid tumors.
To stay updated on Kura's progress and the developments in their research, stakeholders and interested parties are encouraged to follow Kura on their professional social media channels and explore updates on their website.
Frequently Asked Questions
What is the focus of the upcoming virtual events hosted by Kura Oncology?
The events will spotlight Kura's innovative farnesyl transferase inhibitor program, discussing preclinical and clinical data related to their cancer treatment strategies.
When are the events scheduled to take place?
The first event is on September 16, while the second event will occur on October 18, both in 2025.
Where can I access the live webcasts for these events?
The webcasts will be available in the Investors section of Kura's website, with recordings available afterward.
What are some key studies to be presented at the ESMO Congress?
The studies include preliminary results of KO-2806 in renal cell carcinoma and insights into its combination therapies.
What opportunities does Kura Oncology offer in cancer treatment innovation?
Kura focuses on developing targeted therapies and innovative treatments to overcome resistance in cancer, aiming to revolutionize patient care in oncology.
